Ryan Viets, MD
Neuroradiology · la Mesa, CANPI 1568617108
Payments from drug & device makers
What this record shows
Penumbra, Inc. accounts for 72.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $2,546 and has fallen 91.8% since, to $208 in 2025.
Across 64 payments — averaging $66.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$3K
- Microvention, Inc.$360
- Johnson & Johnson$317
- Stryker$217
- Medtronic$163
- Vasorum USA Inc.$95
- plus $22 from 1 others
Across 39 payments — averaging $628.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Penumbra, Inc.$25K
What the payments were for
- Travel & lodging$2,24953%
- Food & beverage$2,01847%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 29 | $3,092 |
| Microvention, Inc. | 4 | $360 |
| Johnson & Johnson | 16 | $317 |
| Stryker | 8 | $217 |
| Medtronic | 5 | $163 |
| Vasorum USA Inc. | 1 | $95 |
| Life Molecular Imaging Ltd | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Penumbra System$3,508
- Penumbra Coil 400$169
How this compares
$4,266 in reported general payments places this provider in the 70th percentile of 154 neuroradiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 22 | $98 |
Paid to pharmacies, not to this prescriber.
Other neuroradiology in la Mesa
- Aaron BerezMountain View$24.1M
- Amon LiuRedwood City$1.1M
- Fabio SettecaseSan Francisco$758K
- Michael MarksStanford$254K
- Huy DoStanford$226K
- Akash KansagraStanford$179K
- Bradley JabourSanta Monica$156K
- Christopher PutmanTorrance$148K
- Nicholas TelischakStanford$148K
- Jay AcharyaWest Hollywood$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.